Khurana M - Search Results

1

Urine proteomic profiling of pediatric nephrotic syndrome.

Khurana M, Traum AZ, Aivado M, Wells MP, Guerrero M, Grall F, Libermann TA, Schachter AD. Khurana M, et al. Pediatr Nephrol. 2006 Sep;21(9):1257-65. doi: 10.1007/s00467-006-0165-8. Epub 2006 Jun 30. Pediatr Nephrol. 2006. PMID: 16810512 Free PMC article.

2

Allograft rejection and glomerular basement membrane antibodies in Alport's syndrome.

Charytan D, Torre A, Khurana M, Nicastri A, Stillman IE, Kalluri R. Charytan D, et al. Among authors: khurana m. J Nephrol. 2004 May-Jun;17(3):431-5. J Nephrol. 2004. PMID: 15365966

3

Cinacalcet is efficacious in pediatric dialysis patients.

Silverstein DM, Kher KK, Moudgil A, Khurana M, Wilcox J, Moylan K. Silverstein DM, et al. Among authors: khurana m. Pediatr Nephrol. 2008 Oct;23(10):1817-22. doi: 10.1007/s00467-007-0742-5. Epub 2008 Feb 21. Pediatr Nephrol. 2008. PMID: 18288502

4

Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease.

Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, Werner MC, Shield CF 3rd, Werb Z, Kalluri R. Zeisberg M, et al. Among authors: khurana m. PLoS Med. 2006 Apr;3(4):e100. doi: 10.1371/journal.pmed.0030100. Epub 2006 Mar 7. PLoS Med. 2006. PMID: 16509766 Free PMC article.

5

Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.

Khurana M, Silverstein DM. Khurana M, et al. Pediatr Nephrol. 2015 Dec;30(12):2073-84. doi: 10.1007/s00467-015-3075-9. Epub 2015 Mar 24. Pediatr Nephrol. 2015. PMID: 25801207 Review.

6

Dosing Recommendations for Pediatric Patients With Renal Impairment.

Al-Khouja A, Park K, Anderson DJC, Young C, Wang J, Huang SM, Khurana M, Burckart GJ. Al-Khouja A, et al. Among authors: khurana m. J Clin Pharmacol. 2020 Dec;60(12):1551-1560. doi: 10.1002/jcph.1676. Epub 2020 Jun 15. J Clin Pharmacol. 2020. PMID: 32542790 Free PMC article.

7

Renal Impairment in Pediatric Patients: Current Approaches to Drug Dosing.

Khurana M. Khurana M. J Clin Pharmacol. 2021 Jun;61 Suppl 1:S161-S164. doi: 10.1002/jcph.1908. J Clin Pharmacol. 2021. PMID: 34185911 No abstract available.

8

Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies.

Bird ST, Swain RS, Tian F, Okusanya OO, Waldron P, Khurana M, Durmowicz EL, Ma Y, Major JM, Gelperin K. Bird ST, et al. Among authors: khurana m. Lancet Child Adolesc Health. 2019 Jan;3(1):15-22. doi: 10.1016/S2352-4642(18)30335-3. Epub 2018 Nov 17. Lancet Child Adolesc Health. 2019. PMID: 30455109

9

Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration.

Zhang Y, Wang Y, Khurana M, Sachs HC, Zhu H, Burckart GJ, Alexander J, Yao LP, Wang J. Zhang Y, et al. Among authors: khurana m. Clin Pharmacol Ther. 2020 Jul;108(1):90-98. doi: 10.1002/cpt.1809. Epub 2020 Mar 16. Clin Pharmacol Ther. 2020. PMID: 32030741

10

Creatinine-Based Renal Function Assessment in Pediatric Drug Development: An Analysis Using Clinical Data for Renally Eliminated Drugs.

Zhang Y, Sherwin CM, Gonzalez D, Zhang Q, Khurana M, Fisher J, Burckart GJ, Wang Y, Yao LP, Ganley CJ, Wang J. Zhang Y, et al. Among authors: khurana m. Clin Pharmacol Ther. 2021 Jan;109(1):263-269. doi: 10.1002/cpt.1991. Epub 2020 Aug 29. Clin Pharmacol Ther. 2021. PMID: 32696977 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

206 results

Search Page